Literature DB >> 3264122

Cigarette smoking and lung cancer in New Mexico.

J M Samet1, C L Wiggins, C G Humble, D R Pathak.   

Abstract

We have used population-based data for the state of New Mexico to calculate cigarette-smoking-specific incidence rates for lung cancer, cumulative incidence rates for lung cancer, and estimates of the proportion of lung cancer cases attributable to smoking. For white New Mexicans, the incidence of lung cancer increased with age and was markedly higher in smokers than in nonsmokers. From 25 through 84 yr of age, the cumulative incidence of lung cancer was 0.9% in nonsmoking males and 0.5% in nonsmoking females. The cumulative incidence rates were much higher for smokers; for males who smoked 20 or more cigarettes daily from age 25, the cumulative risk of lung cancer through age 84 was 31.7%. For females with the same cigarette smoking history, the estimate of cumulative incidence through age 84 years was 15.3%. The population-attributable risks for lung cancer associated with cigarette smoking were 89.5% for males and 85.5% for females.

Entities:  

Mesh:

Year:  1988        PMID: 3264122     DOI: 10.1164/ajrccm/137.5.1110

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  9 in total

Review 1.  Genetic testing for lung cancer risk: if physicians can do it, should they?

Authors:  Theodore W Marcy; Michael Stefanek; Kimberly M Thompson
Journal:  J Gen Intern Med       Date:  2002-12       Impact factor: 5.128

2.  Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.

Authors:  Wusheng Yan; Ignacio I Wistuba; Michael R Emmert-Buck; Heidi S Erickson
Journal:  Am J Cancer Res       Date:  2011-01-01       Impact factor: 6.166

3.  Incidence of Non-Salivary Gland Neoplasms in Patients with Warthin Tumor: A Study of 73 Cases.

Authors:  Daniel J Zaccarini; Kamal K Khurana
Journal:  Head Neck Pathol       Date:  2019-06-21

Review 4.  Lung cancer in never smokers: clinical epidemiology and environmental risk factors.

Authors:  Jonathan M Samet; Erika Avila-Tang; Paolo Boffetta; Lindsay M Hannan; Susan Olivo-Marston; Michael J Thun; Charles M Rudin
Journal:  Clin Cancer Res       Date:  2009-09-15       Impact factor: 12.531

5.  Clinical characteristics of Japanese lung cancer patients with human immunodeficiency virus infection.

Authors:  Yusuke Okuma; Naoki Yanagisawa; Yusuke Takagi; Yukio Hosomi; Akihiko Suganuma; Akifumi Imamura; Mari Iguchi; Tatsuru Okamura; Atsushi Ajisawa; Masahiko Shibuya
Journal:  Int J Clin Oncol       Date:  2011-09-16       Impact factor: 3.402

Review 6.  Low-Dose CT Screening for Lung Cancer: Evidence from 2 Decades of Study.

Authors:  David S Gierada; William C Black; Caroline Chiles; Paul F Pinsky; David F Yankelevitz
Journal:  Radiol Imaging Cancer       Date:  2020-03-27

7.  A multi-institutional study of clinicopathological features and molecular epidemiology of epidermal growth factor receptor mutations in lung cancer patients living with human immunodeficiency virus infection.

Authors:  Yusuke Okuma; Junko Tanuma; Hiroshi Kamiryo; Yuki Kojima; Mihoko Yotsumoto; Atsushi Ajisawa; Tomoko Uehira; Hirokazu Nagai; Yuichiro Takeda; Yasuhiro Setoguchi; Seiji Okada
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-24       Impact factor: 4.553

8.  Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers.

Authors:  Tomomi W Nobashi; Yuko Nishimoto; Yujiro Kawata; Hidetaka Yutani; Masaki Nakamura; Yuichi Tsuji; Atsushi Yoshida; Akihiko Sugimoto; Takayuki Yamamoto; Israt S Alam; Satoshi Noma
Journal:  Br J Radiol       Date:  2020-08-12       Impact factor: 3.039

9.  Physical activity among lung cancer survivors: changes across the cancer trajectory and associations with quality of life.

Authors:  Elliot J Coups; Bernard J Park; Marc B Feinstein; Richard M Steingart; Brian L Egleston; Donna J Wilson; Jamie S Ostroff
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02-03       Impact factor: 4.254

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.